Does finerenone reduce NT-proBNP levels and clinical events compared to eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease?
Patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Finerenone (including a 10 to 20 mg dose group)
Eplerenone
30% or greater decrease in NT-proBNP levelssurrogate
Finerenone is well tolerated and similarly effective to eplerenone in reducing NT-proBNP in patients with worsening chronic heart failure and diabetes or CKD.
Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone. The finding of reduced clinical events in the finerenone 10→20 mg group should be further explored in a large outcomes trial.
Building similarity graph...
Analyzing shared references across papers
Loading...
Gerasimos Filippatos
Stefan D. Anker
Michael Böhm
European Heart Journal
University of Michigan
Inserm
Northwestern University
Building similarity graph...
Analyzing shared references across papers
Loading...
Filippatos et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d5708e75589c71d767dd11 — DOI: https://doi.org/10.1093/eurheartj/ehw132